Genscript Biotech Corporation (G51) — Working Capital to Net Assets Ratio
Genscript Biotech Corporation (G51) has a Working Capital to Net Assets ratio of 9.0% as of December 2025. Working capital of €358.80 Million (current assets of €1.08 Billion minus current liabilities of €720.17 Million) is measured against net assets of €3.96 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Genscript Biotech Corporation (G51) net asset quality to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Genscript Biotech Corporation Working Capital to Net Assets (2016–2025)
This chart shows how Genscript Biotech Corporation's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2016 to 2025. As of December 2025, the ratio stands at 9.0%, reflecting working capital of €358.80 Million against net assets of €3.96 Billion EUR. Check G51 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Genscript Biotech Corporation (2016–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Genscript Biotech Corporation from 2016 to 2025, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Genscript Biotech Corporation worth.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.0% | €358.80 Million | €3.96 Billion | €1.08 Billion | €720.17 Million | ▼ -3.2 pp |
| 2024 | 12.2% | €527.64 Million | €4.32 Billion | €834.98 Million | €307.34 Million | ▼ -78.7 pp |
| 2023 | 90.9% | €1.86 Billion | €2.04 Billion | €2.35 Billion | €494.81 Million | ▲ +1.4 pp |
| 2022 | 89.5% | €1.22 Billion | €1.36 Billion | €1.76 Billion | €545.98 Million | ▼ -17.9 pp |
| 2021 | 107.4% | €1.17 Billion | €1.09 Billion | €1.64 Billion | €464.37 Million | ▲ +25.8 pp |
| 2020 | 81.6% | €665.26 Million | €815.59 Million | €993.17 Million | €327.91 Million | ▼ -6.9 pp |
| 2019 | 88.5% | €329.54 Million | €372.30 Million | €554.05 Million | €224.50 Million | ▼ -18.1 pp |
| 2018 | 106.6% | €525.95 Million | €493.30 Million | €679.46 Million | €153.51 Million | ▲ +51.8 pp |
| 2017 | 54.8% | €125.18 Million | €228.32 Million | €397.89 Million | €272.72 Million | ▼ -12.9 pp |
| 2016 | 67.8% | €124.69 Million | €184.02 Million | €163.91 Million | €39.22 Million | — |